<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Epidemiol Biomarkers Prev</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Epidemiol Biomarkers Prev</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</journal-title></journal-title-group><issn pub-type="ppub">1055-9965</issn><issn pub-type="epub">1538-7755</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10773003</article-id><article-id pub-id-type="pmcid-ver">PMC10773003.1</article-id><article-id pub-id-type="pmcaid">10773003</article-id><article-id pub-id-type="pmcaiid">10773003</article-id><article-id pub-id-type="manuscript-id">NIHMS1916169</article-id><article-id pub-id-type="pmid">37410096</article-id><article-id pub-id-type="doi">10.1158/1055-9965.EPI-23-0420</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1916169</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1916169</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Streck</surname><given-names initials="JM">Joanna M.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="JW">Ju-Whei</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walter</surname><given-names initials="AW">Angela Wangari</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosen</surname><given-names initials="RL">Rachel L.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gareen</surname><given-names initials="IF">Ilana F.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kircher</surname><given-names initials="SM">Sheetal Mehta</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Herman</surname><given-names initials="BA">Benjamin A.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carlos</surname><given-names initials="RC">Ruth C.</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="S">Shaji</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mayer</surname><given-names initials="IA">Ingrid A.</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saba</surname><given-names initials="NF">Nabil F.</given-names></name><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fenske</surname><given-names initials="TS">Timothy S.</given-names></name><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Neal</surname><given-names initials="JW">Joel W.</given-names></name><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Atkins</surname><given-names initials="MB">Michael B.</given-names></name><xref rid="A12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hodi</surname><given-names initials="FS">F. Stephen</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kyriakopoulos</surname><given-names initials="CE">Christos E.</given-names></name><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tempany</surname><given-names initials="C">Clare</given-names></name><xref rid="A14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shanafelt</surname><given-names initials="TD">Tait D.</given-names></name><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wagner</surname><given-names initials="LI">Lynne I.</given-names></name><xref rid="A15" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Land</surname><given-names initials="SR">Stephanie R.</given-names></name><xref rid="A16" ref-type="aff">16</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="ER">Elyse R.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ostroff</surname><given-names initials="JS">Jamie S.</given-names></name><xref rid="A17" ref-type="aff">17</xref></contrib></contrib-group><aff id="A1"><label>1</label>Massachusetts General Hospital/Harvard Medical School</aff><aff id="A2"><label>2</label>Dana-Farber Cancer Institute/ECOG-ACRIN Biostatistics Center</aff><aff id="A3"><label>3</label>University of Massachusetts Lowell</aff><aff id="A4"><label>4</label>Brown University</aff><aff id="A5"><label>5</label>Northwestern University</aff><aff id="A6"><label>6</label>University of Michigan</aff><aff id="A7"><label>7</label>Mayo Clinic</aff><aff id="A8"><label>8</label>Vanderbilt University</aff><aff id="A9"><label>9</label>Emory University</aff><aff id="A10"><label>10</label>Medical College of Wisconsin</aff><aff id="A11"><label>11</label>Stanford University</aff><aff id="A12"><label>12</label>Georgetown University Hospital</aff><aff id="A13"><label>13</label>University of Wisconsin-Madison</aff><aff id="A14"><label>14</label>Brigham and Women&#8217;s Hospital/Harvard Medical School</aff><aff id="A15"><label>15</label>Wake Forest University</aff><aff id="A16"><label>16</label>National Cancer Institute</aff><aff id="A17"><label>17</label>Memorial Sloan Kettering Cancer Center</aff><author-notes><corresp id="CR1"><bold>Correspondence:</bold> Joanna M. Streck, Ph.D., Tobacco Research and Treatment Center, 100 Cambridge Street, 16<sup>th</sup> Floor, Massachusetts General Hospital &amp; Harvard Medical School, P: 617-643-9977, <email>jstreck@mgh.harvard.edu</email></corresp><fn id="FN1"><p id="P1">Roles:</p><p id="P2">Conceptualization- JMS, JSO</p><p id="P3">Funding Acquisition- LIW, ERP, JSO, IFG</p><p id="P4">Data Analysis- JL</p><p id="P5">Initial draft of the manuscript- JMS, JSO</p><p id="P6">All authors have read and approved of the final manuscript and consent to publication.</p></fn><fn fn-type="COI-statement" id="FN2"><p id="P35"><underline>Disclosures</underline>: No conflicts of interest to declare.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>11</month><year>2023</year></pub-date><volume>32</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">452778</issue-id><fpage>1552</fpage><lpage>1557</lpage><pub-history><event event-type="nihms-submitted"><date><day>21</day><month>07</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 16:25:15.287"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1916169.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P7">While cigarette smoking has declined among the US general population, sale and use of non-cigarette alternative tobacco products (ATPs; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among cancer patients in national trials.</p></sec><sec id="S2"><title>Methods:</title><p id="P8">Cancer survivors (N=756) enrolled in 9 ECOG-ACRIN clinical trials (2017-2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30-days (30d).</p></sec><sec id="S3"><title>Results:</title><p id="P9">Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30d, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30d. Males (vs. females) (OR 4.33; p=0&lt;.01) and individuals not living with another person who smokes (vs. living with) (OR 8.07; p=0&lt;.01) were more likely to use ATPs only vs. cigarettes only in the past 30d.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P10">Among cancer patients, cigarettes were the most prevalent tobacco product reported.</p></sec><sec id="S5"><title>Impact:</title><p id="P11">Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.</p></sec></abstract><kwd-group><kwd>Alternative tobacco products</kwd><kwd>dual use</kwd><kwd>e-cigarettes</kwd><kwd>cigarettes</kwd><kwd>cigars</kwd><kwd>cancer patients</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>